Literature DB >> 15755996

Up-regulation of the peripheral benzodiazepine receptor during human colorectal carcinogenesis and tumor spread.

Kerstin Maaser1, Patricia Grabowski, Yelda Oezdem, Antje Krahn, Bernhard Heine, Harald Stein, Heinz Buhr, Martin Zeitz, Hans Scherübl.   

Abstract

The peripheral benzodiazepine receptor (PBR) is overexpressed in a variety of cancers. In Unio Internationale Contra Cancrum (UICC) III colorectal cancers, a high level of PBR overexpression correlates with poor prognosis. However, little is known about the role of PBR in the development and progression of colorectal cancer. This study addresses the up-regulation of PBR during colorectal carcinogenesis and tumor spread. One hundred sixteen consecutive patients undergoing surgery for colorectal cancer with either regional (59 patients) or distant metastases (57 patients) were followed-up for 5 years or until death. Twenty-four of the 59 patients with initial UICC stage III cancers later developed distant metastases. PBR overexpression in tumor specimens was determined by immunohistochemistry. UICC stage III patients with colorectal primaries highly overexpressing PBR developed metastases significantly more often than patients with low PBR overexpression in their primary carcinoma. In 54 of the 116 patients adenomas and/or metastases and/or recurrences were available to be studied for PBR up-regulation during colorectal carcinogenesis and tumor spread. PBR was found to be overexpressed in 86% of early and late adenomas. Furthermore, 85% of primaries and of 86% of metastases displayed PBR overexpression. PBR overexpression was also detected at the mRNA level as revealed by real-time PCR. The extent of PBR protein overexpression was equivalent in colorectal adenomas and carcinomas but slightly increased in metastases. These data suggest a functional role of PBR during colorectal carcinogenesis and tumor spread. Thus, PBR qualifies as a target for innovative diagnostic and therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755996     DOI: 10.1158/1078-0432.CCR-04-1955

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress.

Authors:  Joanna Klubo-Gwiezdzinska; Kirk Jensen; Andrew Bauer; Aneeta Patel; John Costello; Kenneth D Burman; Leonard Wartofsky; Matthew J Hardwick; Vasyl V Vasko
Journal:  J Endocrinol       Date:  2012-05-29       Impact factor: 4.286

2.  TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis, and a growth-promoting metabolic shift toward glycolysis in glioblastoma.

Authors:  Yi Fu; Dongdong Wang; Huaishan Wang; Menghua Cai; Chao Li; Xue Zhang; Hui Chen; Yu Hu; Xuan Zhang; Mingyao Ying; Wei He; Jianmin Zhang
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

3.  Microwave-assisted Organic Synthesis of a High-affinity Pyrazolo-pyrimidinyl TSPO Ligand.

Authors:  Dewei Tang; Jason R Buck; Matthew R Hight; H Charles Manning
Journal:  Tetrahedron Lett       Date:  2010-09-01       Impact factor: 2.415

4.  Mitochondrial Translocator Protein (TSPO) Function Is Not Essential for Heme Biosynthesis.

Authors:  Amy H Zhao; Lan N Tu; Chinatsu Mukai; Madhu P Sirivelu; Viju V Pillai; Kanako Morohaku; Roy Cohen; Vimal Selvaraj
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

5.  Overexpression of translocator protein in inflammatory bowel disease: potential diagnostic and treatment value.

Authors:  Mariano A Ostuni; Leeyah Issop; Gabriel Péranzi; Francine Walker; Magali Fasseu; Carole Elbim; Vassilios Papadopoulos; Jean-Jacques Lacapere
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

Review 6.  Targeting mitochondria for cancer therapy.

Authors:  Simone Fulda; Lorenzo Galluzzi; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2010-05-14       Impact factor: 84.694

7.  TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control.

Authors:  Jemma Gatliff; Daniel East; James Crosby; Rosella Abeti; Robert Harvey; William Craigen; Peter Parker; Michelangelo Campanella
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

8.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.

Authors:  M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12-11       Impact factor: 8.090

9.  PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect.

Authors:  Tiziana Musacchio; Valentino Laquintana; Andrea Latrofa; Giuseppe Trapani; Vladimir P Torchilin
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

10.  The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.

Authors:  Maria C Mendonça-Torres; Stephen S Roberts
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.